Study Group: Gastroenterologists (US)(?)
Council Members in this Study Group: 820
Request a survey with this Study Group
Leading Experts in this Study Group
Hepatologist and Gastroenterologist
Miami Gastroenterology Consultants PA
Miguel Rodriguez, MD, is a Hepatologist & Gastroenterologist, Managing Partner of Miami Gastroenterology Consultants, PA., a single specialty group in Miami, Florida. He is former Assistant Professor of Medicine of the University of Miami School of Medicine and Center for Liver Diseases and Division...
Professor of Clinical Medicine
University of Miami School of Medicine
Christopher O'Brien, MD, is Professor of Clinical Medicine in the Hepatology Division at the University of Miami Miller School of Medicine, Florida. Dr. O'Brien has been published numerous times and has extensive research experience in Hepatitis B and C. He is a member of the American Gastroenterology...
Carlos Dujovne, MDProfessor of Medicine and Director
OREGON HEALTH & SCIENCE UNIVERSITY - CC
Carlos Dujovne, MD, is an Internist, Gastroenterologist, Clinical Pharmacologist, Certified Clinical Lipidologist, Fr. Prof. of Medicine and Pharmacology, and Director of Clinical Pharmacology's Lipid-Arteriosclerosis Prevention-Treatment Clinic in Dept. of Medicine and Pharmacology at University of...
Associate Professor of Clinical Medicine
Georgetown University - CC
Averell Sherker, MD, FRCP, is Director of the Center for Liver Diseases at Washington Hospital Center in Washington, DC. He is also Associate Professor of Clinical Medicine at Georgetown University. Previously, Dr. Sherker was Director of Hepatology Research at the McGill University in Canada, where...
Michael BlumeGastroenterologist
Metropolitan Medical Associates
Michael Blume, MD, is a Gastroenterologist at the Metropolitan Medical Associates in Baltimore, Maryland. In addition to being in full-time private practice, he has extensive experience in utilization management and quality improvement. Dr. Blume has done consulting work for various clinical efficiency...
Eugene Schiff, MD, MACP, FRCP, MACGDirector of Center for Liver Diseases
University of Miami School of Medicine
Eugene Schiff, MD, MACP, FRCP, FAGA, MACG, AGAF, is a Leonard Miller Professor of Medicine and Director of the Center for Liver Diseases at the University of Miami School of Medicine. Dr. Schiff is fellowship trained in gastroenterology. He is the co-editor of the tenth edition of Schiff’s Diseases...
Related Study Groups
| Study Group Name | Members |
|---|---|
| Physicians who Treat GERD (US) | 359 |
| Gastroenterologists who Treat GERD | 367 |
| Gastroenterologists in Private Practice (US) | 196 |
| IBD Gastroenterologists (US) | 167 |
| IBD Gastroenterologists | 303 |
| Hepatologists (US) | 84 |
| Physicians who Treat Ulcerative Colitis (US) | 71 |
GLG NewsSMAnalyses by this Study Group's Leading Experts(?)
High blood acetaldehyde levels are associated with more liver and perhaps pancreatic damage and inflammation thus enhancing neoplasia. How would high blood acetaldehyde levels induce colorectal cancer? Also through inflammation. The alcohol dehydrogenase polymorphism is common in Asians yet there is...
Previous 'simple' molecular tests for cancer have ussually not worked out in practice. Although microRNA's have cellular control function for multiple genes it is premature to believe that these tests will be more successful.
GERD is a motility disorder, but this particular agent (Xenoport 19986) has again failed to provide significant proof for any benefit in the targeted symptomatic population. Additional studies may or may not lead to a niche for this product.
Crestor's results in the Jupiter Study likely to change medical-economic perspectives in statin choices.
1:Crestor is the most potent statin in the market,yet is 3d in sales behind Zocor and Lipitor.2:The efficacy supriority together with its capacity to lower CRP levels led to the highest rate of ASCVD prevention in the shortest period of time evr documented in statin trials.3:The trial in near 18,000...
1) telaprevir appears to improve therapy in hard to treat genotype one. 2)previous treatment failures have a reason to now be retreated. 3)naive treatment patients have better chance for cure with the possibility of only 6 month rather than 12 moths of therapy
Most Common Company Types:
- Academic Medical Center/Hospital or Clinic
- Office Based Private Practice or Clinic
- Academic Institution*
- Non-Academic Community Hospital or Clinic
Most Common Job Types:
- Physician - Attending Physician
- Physician - Director
- Owner
- Physician - Division Head
- Professor
- Director